Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Morphologic Assessment of Terminal Erythroid Differentiation Predicts Outcomes in Myelodysplastic Syndromes

Maria Julia Montoro, MD, Ana Perez, MD, Silvia Saumell, MD PhD, Maida Navarrete, MD, Gael Roue, PhD, Moraima Jimenez, MD, Margarita Ortega, PhD, Bárbara Tazón, PhD, Antonieta Molero, MD, Olga Salamero, MD, Francesc Bosch, MD PhD, David Valcarcel, MD

Blood (2019) 134 (Supplement_1): 3011.

https://doi.org/10.1182/blood-2019-123185

Published: 2019

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Blood (2018) 132 (Supplement 1): 1385.

https://doi.org/10.1182/blood-2018-99-110895

Published: 2018

Journal Articles

The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma

Juan G Valero, PhD, Aranzazu Chamorro-Jorganes, PhD, Katie Walker, PhD, Martina Guerrero-Hernandez, MSc, Vanina Rodriguez, Clara Recasens-Zorzo, MSc, Anna Esteve-Arenys, MSc, Eriong Lee-Verges, MSc, Alba Matas-Cespedes, PhD, Neus Serrat, PhD, Dolors Colomer, PhD, Armando Lopez-Guillermo, Stacey Tannheimer, PhD, Patricia Pérez-Galán, PhD, Gael Roue, PhD

Blood (2017) 130 (Supplement 1): 4108.

https://doi.org/10.1182/blood.V130.Suppl_1.4108.4108

Published: 2017

Journal Articles

Idelalisib Interferes with the Crosstalk of Follicular Lymphoma and Its Immune Microenvironment and Potentiates the Activity of ABT-199

Martina Guerrero-Hernandez, MSc, Alba Matas-Cespedes, PhD, Neus Serrat, PhD, Anella Yahiaoui, BS, Juan G Valero, PhD, Laura Magnano, MD, Alfredo Rivas-Delgado, MD, Dolors Colomer, PhD, Elias Campo, MD PhD, Armando Lopez-Guillermo, Gael Roue, PhD, Stacey Tannheimer, PhD, Patricia Pérez-Galán, PhD

Blood (2017) 130 (Supplement 1): 2813.

https://doi.org/10.1182/blood.V130.Suppl_1.2813.2813

Published: 2017

Journal Articles

Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions

Alba Matas-Céspedes, MS, Anna Vidal-Crespo, MS, Vanina Rodriguez, Julio Delgado, MD PhD, Neus Villamor, MD PhD, Gael Roue, PhD, Elías Campo, MD PhD, Dolors Colomer, PhD, Parul Doshi, PhD, Adrian Wiestner, MD PhD, Paul W.H.I. Parren, PhD, Jeroen Lammerts van Bueren, PhD, Patricia Pérez-Galán, PhD

Blood (2014) 124 (21): 4680.

https://doi.org/10.1182/blood.V124.21.4680.4680

Published: 2014

Journal Articles

Follicular Dendrytic Cells Deliver Angiogenesis Signaling To Follicular Lymphoma Cells That Is Hampered By The Pan-PI3K Inhibitor NVP-BKM120

Alba Matas-Céspedes, MS, Vanina Rodriguez, Susana Kalko, PhD, Eva Gine, MD, PhD, Elias Campo, MD, PhD, Gael Roue, PhD, Armando Lopez-Guillermo, MD, PhD, Dolors Colomer, PhD, Perez-Galan Patricia, PhD

Blood (2013) 122 (21): 3072.

https://doi.org/10.1182/blood.V122.21.3072.3072

Published: 2013

Journal Articles

Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL

Alba Matas-Céspedes, MS, Anna Vidal Crespo, MS, Vanina Rodriguez, Gael Roue, PhD, Armando Lopez-Guillermo, MD, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD, Jeroen Lammerts van Bueren, PhD, Joost M Bakker, PhD, Adrian Wiestner, MD, PhD, Paul W.H.I. Parren, PhD, Patricia Perez-Galan, PhD

Blood (2013) 122 (21): 378.

https://doi.org/10.1182/blood.V122.21.378.378

Published: 2013

Journal Articles

The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma

Silvia Xargay-Torrent, BS, Monica López-Guerra, PhD, Ifigènia Saborit-Villarroya, PhD, Laia Rosich, BS, Alba Navarro, BS, Neus Villamor, MD, PhD, Marta Aymerich, MD, PhD, Patricia Perez-Galan, PhD, Gael Roue, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD

Blood (2012) 120 (21): 1647.

https://doi.org/10.1182/blood.V120.21.1647.1647

Published: 2012

Journal Articles

Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Alba Matas-Céspedes, BS, Anna Vidal-Crespo, BS, Vanina Rodriguez, Gael Roue, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD, Jeroen Lammerts van Bueren, PhD, Joost M Bakker, PhD, Adrian Wiestner, MD, PhD, Paul W.H.I. Parren, PhD, Patricia Perez-Galan, PhD

Blood (2012) 120 (21): 3935.

https://doi.org/10.1182/blood.V120.21.3935.3935

Published: 2012

Journal Articles

The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma

Arnau Montraveta, MS, Mercè de Frías, PhD, Clara Campàs, PhD, Elias Campo, MD, PhD, Gael Roue, PhD, Dolors Colomer, PhD

Blood (2010) 116 (21): 3918.

https://doi.org/10.1182/blood.V116.21.3918.3918

Published: 2010

Journal Articles

The Expression of the ER Stress Sensor GRP78/Bip Is a Target of R-CHOP and Bortezomib Treatments in DLBCL with Prognostic Value. A Rationale for the Use of Proteasome Inhibitors in DLBCL Patients.

Ana Mozos, Gael Roue, PhD, Armando López-Guillermo, Pedro Jares, Dolors Colomer, Elias Campo, MD, PhD, Antonio Martinez, MD, PhD

Blood (2009) 114 (22): 3734.

https://doi.org/10.1182/blood.V114.22.3734.3734

Published: 2009

Journal Articles

BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.

Patricia Perez Galan, PhD, Gael Roue, PhD, Monica Lopez Guerra, BS, Neus Villamor, MD, PhD, Emili Montserrat, MD, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD

Blood (2007) 110 (11): 3464.

https://doi.org/10.1182/blood.V110.11.3464.3464

Published: 2007

Journal Articles

The Novel HSP90 Inhibitor IPI-504 Synergizes with Bortezomib in Mantle Cell Lymphoma Cells by Targeting Both NF-kappaB Signaling and Unfolded Protein Response and Leading to Increased Mitochondrial Apoptosis.

Gael Roue, PhD, Patricia Perez-Galan, PhD, Monica Lopez-Guerra, BS, Neus Villamor, PhD, MD, Elias Campo, PhD, MD, Dolors Colomer, PhD

Blood (2007) 110 (11): 1601.

https://doi.org/10.1182/blood.V110.11.1601.1601

Published: 2007

Journal Articles

c-FLIP Level Determines the Sensitivity of Mantle Cell Lymphoma Cells to TRAIL-Induced Apoptosis Following Inhibition of NFkB Signalling or Proteasome Activity.

Gael Roue, PhD, Patricia Perez Galan, PhD, Neus Villamor, MD, PhD, Elies Campo, MD, Dolors Colomer, PhD

Blood (2005) 106 (11): 4820.

https://doi.org/10.1182/blood.V106.11.4820.4820

Published: 2005

Journal Articles

The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib.

Patricia Perez Galan, PhD, Gael Roue, PhD, Neus Villamor, PhD, MD, Elias Campo, PhD, MD, Dolors Colomer, PhD

Blood (2005) 106 (11): 1490.

https://doi.org/10.1182/blood.V106.11.1490.1490

Published: 2005

Journal Articles

Cyclin D1 Mediates Resistance towards p53-Independent and -Dependent Apoptosis through Anti-Apoptotic Factors and Molecular Chaperones.

Gael Roue, PhD, Vianney Pichereau, PhD, Hubert Lincet, PhD, Xavier Troussard, MD, Brigitte Sola, PhD

Blood (2005) 106 (11): 4294.

https://doi.org/10.1182/blood.V106.11.4294.4294

Published: 2005

NARROW

Morphologic Assessment of Terminal Erythroid Differentiation Predicts Outcomes in Myelodysplastic Syndromes

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma

Idelalisib Interferes with the Crosstalk of Follicular Lymphoma and Its Immune Microenvironment and Potentiates the Activity of ABT-199

Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions

Follicular Dendrytic Cells Deliver Angiogenesis Signaling To Follicular Lymphoma Cells That Is Hampered By The Pan-PI3K Inhibitor NVP-BKM120

Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL

The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma

Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma

The Expression of the ER Stress Sensor GRP78/Bip Is a Target of R-CHOP and Bortezomib Treatments in DLBCL with Prognostic Value. A Rationale for the Use of Proteasome Inhibitors in DLBCL Patients.

BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.

The Novel HSP90 Inhibitor IPI-504 Synergizes with Bortezomib in Mantle Cell Lymphoma Cells by Targeting Both NF-kappaB Signaling and Unfolded Protein Response and Leading to Increased Mitochondrial Apoptosis.

c-FLIP Level Determines the Sensitivity of Mantle Cell Lymphoma Cells to TRAIL-Induced Apoptosis Following Inhibition of NFkB Signalling or Proteasome Activity.

The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib.

Cyclin D1 Mediates Resistance towards p53-Independent and -Dependent Apoptosis through Anti-Apoptotic Factors and Molecular Chaperones.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only